Gilead plans to go straight to Phase III studies for once-yearly lenacapavir, while GSK and Viiv will push forward with their ...
NEW YORK, NY / ACCESS Newswire / March 9, 2025 / If you suffered a loss on your GSK plc (NYSE:GSK) investment and want to learn about a potential recovery under the federal securities laws ...
GSK has reached an agreement that it says will resolve 93% of the outstanding lawsuits brought against the company claiming that its gastrointestinal drug Zantac caused cancer. The company has ...
GSK paying $25 million upfront, with milestone payments taking the value of the deal up to $262 million. Other drugs in development for CHB include Dicerna (now part of Novo Nordisk) and Roche’s ...
Hikma Pharmaceuticals (HKMPF) is in talks with partners across the world to prepare to sell a generic version of Ozempic and Wegovy, as patents ...
↳ O intercâmbio também é bem visto por ajudar a aprimorar um novo idioma. Empresa júnior ... projetos para mais de 100 empresas, como GSK, ExxonMobil, Unilever, Mercado Livre, Ball ...
Copyright © 2025 MarketWatch, Inc. All rights reserved.
After hours: March 13 at 7:58:06 p.m. EDT Loading Chart for GSK ...
Latest agreement expands access to the PHCS and MultiPlan Networks SAN DIEGO--(BUSINESS WIRE)--#5hmC--ClearNote Health, a company focused on improving early detection for some of the deadliest cancers ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback